

# Prognosis of soft tissue sarcomas

- Local recurrence : 20 - 30 %
- Metastasis : 30 - 50 %
- Overall survival : 40 - 60 %

# **Soft tissue sarcomas**

## ***Treatment***

- **Aims of treatment**
- **Difficulty of treatment**
- **Multidisciplinary approach**
- **Importance of initial treatment**

# Soft tissue sarcomas

## *Treatment*

- **Natural history**
- **Initial evaluation**
- **Therapeutic tools**
- **Indications**

# Soft tissue sarcomas


## *Natural history*

- **Locoregional extension**
- **Metastases**

# Soft tissue sarcomas

## *Locoregional extension*


- **Pseudo encapsulation**
- **Superficial tumors**
- **Intra-compartmental tumors**
- **Extra-compartmental tumors**
- **Lymph node extension**




# Soft tissue sarcomas

## *Locoregional extension*

- Pseudo encapsulation
- **Superficial tumors**
- Intra-compartmental tumors
- Extra-compartmental tumors
- Lymph node extension






# Soft tissue sarcomas

## *Locoregional extension*

- Pseudo encapsulation
- Superficial tumors
- **Intra-compartmental tumors**
- **Extra-compartmental tumors**
- Lymph node extension



# Soft tissue sarcomas

## Compartments

### Intra comp.

- Superficial
- leg comp.
- Thigh comp.
- buttock
- forearm comp.
- Arm comp.
- periscapular

### Extra comp.

- Superf. and deep
- popliteal area
- inguinal area
- pelvis
- axillary area
- periclavicular
- paraspinal
- head and neck

# Soft tissue sarcomas

## *Lymph node extension*

- Rare (< 5 %)
- Lymph node excision not required
- = M+

# **Soft tissue sarcomas**

## ***Metastases***

- **Vascular extension**
- **Lung**
- **Early metastases**

# Soft tissue sarcomas *Métastases* : *localisations* (Data base GSF - n = 694)

- Lung 70 %
- Lymph node 12 %
- Bone 9 %
- Pleura and peritoneum 8 %
- Liver 7 %
- Others 18 %

# Soft tissue sarcomas

## *Metastases : time of outcome*

*(Data base GSF - n = 694)*

- **Initial** 23 %
- **Before 1 year** 54 %
- **Before 2 years** 77 %
- **Before 5 years** 95 %
- **After 10 years** 1 %

# Soft tissue sarcomas

## *Pre-treatment examination*

- **Locoregional extension :**
  - **clinical examination**
  - **RMI**
  - **CT-scan**
  - **Others**
- **Metastases (lung):**
  - **X-ray**
  - **CT-scan**

OF  
: 1.1

R



10 cm

SE  
A: 180.0  
100/10  
18.0x38.0cm  
190x256  
.0mm  
nc: |  
: 17/2+next  
SE DShort TE TE=10 FOV=20 SW=3 CUISSSE GAUCHE

C: 1799  
W: 3040  
ENHANCED

# **Soft tissue sarcomas**

## ***Therapeutic means***



- **Surgery**
- **Radiotherapy**
- **Chemotherapy**
- **Isolated limb perfusion – TNF**
- **Targeted molecular therapy**

# Soft tissue sarcomas



## *Surgery*

- **Excision**
- **Wide resection**
- **Compartmentectomy**
- **Amputation**


# EXCISION




# WIDE RESECTION









# Soft tissue sarcomas

## *Radiotherapy*

- **Complementary to surgery**
- **Volumes**
- **Doses**
- **Techniques**

# Soft tissue sarcomas

## *Chemotherapy*

- **Efficient drugs :**
  - doxorubicine
  - ifosfamide
- **Efficiency**
- **Toxicity**

# Soft tissue sarcomas

## *Chemotherapy*

- Palliative
- Adjuvant
- Neo-adjuvant




# Isolated limb perfusion with TNF

- Irresectable tumors of the limbs
- ECC of limb + hyperthermy + TNF + melphalan
- Complete response in 50% of cases
- Technically difficult

# Targeted molecular therapy

- **Anti-tyrosine kinases : STI571 (GIST)**
- **New anti-tyrosine kinases**
- **Anti-angiogenic factors**
- **Multi-targeted treatment**

# GIST and STI571



# Treatment of GIST with Glevec


- 80% of immediate non-progression
- about 10% of re-progression during the first year
- minimal efficient dose = 400mg (cost = 2000 euros/month)
- minor secondary effects
- rare major secondary effects
- length of treatment ?
- Problem of progression ?
- Adjuvant treatment ?

# **Soft tissue sarcomas**

## ***Therapeutic decision***

- **Metastases ?**
- **Possible conservative treatment ?**
- **Embryonal histologic type ?**

# Treatment of soft tissue sarcomas



# **Soft tissue sarcomas**

## ***Non-metastatic patients***

- **Loco-regional treatment**
  - Resectable tumor**
    - **conservative surgery**  
**± radiotherapy**
  - Irresectable tumor**
    - **neo-adjuvant chemotherapy**  
**or ILP-TNF**
      - + secondary surgery**
      - + radiotherapy**
- **Adjuvant chemotherapy**

# Soft tissue sarcomas

## Post-treatment-*surveillance*

- **Aims**
- **Rythme**
- **Means**